Marinus Pharma (MRNS) Provides Business Outlook for 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
Marinus Provides Business Outlook for 2020
January 13, 2020 7:30 AM ESTEnrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020
Two additional late-stage clinical trials planned to initiate in 2020
Company presentation and live webcast at 38th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 11:00am PT
RADNOR, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (Marinus or Company), a pharmaceutical company dedicated... More
